La Trobe

File(s) stored somewhere else

Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

journal contribution
posted on 17.12.2020, 22:17 by Verena Börger, Daniel J Weiss, Johnathon D Anderson, Francesc E Borràs, Benedetta Bussolati, David RF Carter, Massimo Dominici, Juan M Falcón-Pérez, Mario Gimona, Andrew HillAndrew Hill, Andrew M Hoffman, Dominique de Kleijn, Bruce L Levine, Rebecca Lim, Jan Lötvall, S Alex Mitsialis, Marta Monguió-Tortajada, Maurizio Muraca, Rienk Nieuwland, Anna Nowocin, Lorraine O'Driscoll, Luis A Ortiz, Donald G Phinney, Ilona Reischl, Eva Rohde, Ralf Sanzenbacher, Clotilde Théry, Wei Seong Toh, Kenneth W Witwer, Sai Kiang Lim, Bernd Giebel
© 2020 International Society for Cell and Gene Therapy STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

History

Publication Date

01/09/2020

Journal

Cytotherapy

Volume

22

Issue

9

Pagination

4p. (p. 482-485)

Publisher

Elsevier

ISSN

1465-3249

Rights Statement

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.